Raymond James Downgrades NGM Biopharmaceuticals (NGM) to Outperform, Following Clinical Business Update
Tweet Send to a Friend
Raymond James analyst Steven Seedhouse downgraded NGM Biopharmaceuticals (NASDAQ: NGM) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
